Medtronic CEO to stay on a little longer as search for successor continues
This article was originally published in Clinica
Executive Summary
Bill Hawkins is to remain CEO of Medtronic for longer than anticipated, as the company has yet to find a suitable replacement. In December, Mr Hawkins announced plans to retire from the post on 29 April, the close of the company's fiscal year (www.clinica.co.uk, 20 December 2010). At the time he said he would remain at the helm until his successor was appointed. However, this seems to have been more difficult than expected; Mr Hawkins said in a letter to employees dated 2 May that the firm's board is making "excellent progress; however, this process takes time and will extend into early FY12".
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.